At a CAGR of 5.2%, Polyclonal Antibody Market to Surpass US$ 1,350.0 Million Globally by End of 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global polyclonal antibody market is estimated to be valued at US$ 943.6 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Polyclonal Antibody Market:

Key trends in the market are the rising incidence of cancer, development of polyclonal antibodies, and adoption of inorganic strategies by key players.

Market players are focusing on the development of novel polyclonal antibodies which is expected to drive the market growth. For instance, in May 2020, SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, announced that SAB-185, its COVID-19 therapeutic candidate for the treatment of novel COVID-19 treatment. This drug is highly-potent neutralizing antibodies to SARS-CoV-2 which are 4 times higher than the most potent human convalescent plasma serum sample evaluated.

Moreover, the increasing incidence of breast cancer is expected to drive the market growth. According to an article published by the World Cancer Research Fund International, in 2018, breast cancer was at second position in the total number of cancer cases worldwide, accounting for 2,088,849 new cases worldwide in 2018.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4347

Key Market Takeaways:

The global polyclonal antibody market is expected to exhibit a CAGR of 5.2% during the forecast period owing to the rising incidence of cancer. According to an article published by the American Cancer Society, in 2017, an estimated 252,710 new cases of invasive breast cancer were diagnosed among women and 2,470 cases in men. In addition to this, 63,410 cases of in situ breast carcinoma were diagnosed among women in the U.S. in 2017.

Furthermore, advantages of polyclonal antibodies are expected to propel the market growth during the forecast period. For instance, an article- Vaccines published by the Multidisciplinary Digital Publishing Institute (MDPI) in August 2020, reported that the advantages of polyclonal antibodies boost commercial production for numerous therapeutics. These advantages include low cost, less invasive nature. The polyclonal antibodies can identify various epitopes on a given antigen and detect small changes within antigens.

Competitive Landscape:

Key players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB. and GeneTex, Inc. among others.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4347

Market Segmentation:

• Global Polyclonal Antibody Market, By Type:
  • Primary Antibody
  • Secondary Antibody
• Global Polyclonal Antibody Market, By Application:
  • Academic Research
  • Commercial
• Global Polyclonal Antibody Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa

Related Market Intelligence Reports:

Antibodies Market, By Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), By Disease Indication (CNS Disorders, Cardiovascular Diseases, Cancer, Autoimmune Disorders), By End User (Hospitals, Long-term Care Facilities, Research institutes), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Read more: https://www.coherentmarketinsights.com/market-insight/antibodies-market-2629

Monoclonal Antibodies Market, by Source (Human, Chimeric, Murine, and Humanized), by Application (Cancer, Autoimmune Disease, Hematological Disease, Infectious Disease, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/monoclonal-antibody-therapeutics-market-2403

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.